Abstract
Background: The accurate and precise quantification of HbA1c is essential for the diagnosis and routine monitoring of patients with diabetes. We report an evaluation of the Trinity Biotech Premier Hb9210 analyser (Bray, Ireland/Kansas City, MO, USA), a boronate affinity chromatography-based high performance liquid chromatography (HPLC) system for the measurement of glycated haemoglobin.
Methods: We evaluated the analytical performance of the Hb9210 as part of a multicentre evaluation. The effect of haemoglobin variants, other potential interferences and the performance in comparison to both the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) and National Glycohemoglobin Standardization Program (NGSP) reference systems, was assessed. Most of the centres participating also act as reference laboratories for both the IFCC standardisation network for HbA1c and the NGSP.
Results: The combined data from all centres showed total coefficients of variation (CV) of 2.71%, 2.32% and 2.14% at low, medium and high values, respectively, for mmol/mol (SI units) and 1.62%, 1.59% and 1.68% for % (NGSP units), which are well below the recommended upper limits of 3% CV for mmol/mol (SI units) and 2% CV for % (NGSP). The analyser showed a good correlation to HbA1c methods currently used in clinical practice and the IFCC reference method procedure. Haemoglobin variants AC, AS, AE and AD do not affect the measurement of HbA1c. Overall the Hb9210 performs well across the whole analytical range.
Conclusions: The Hb9210 performs well and is suitable for clinical application in the analysis of HbA1c.
Acknowledgments
The authors would like to thank Trinity Biotech for the contribution of the instruments and reagents for this evaluation. The authors would like to thank Jeffrey Basilio at the National Institutes for Health and Liesbeth Schröer-Janssen for their contribution running and analysis of the evaluation.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Financial support: This work was funded in part by the Intramural Research Program of the National Institutes of Health (to D.B.S. and Z.Z.).
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus (abbreviated Report of a WHO Consultation), 2011.Search in Google Scholar
2. Standards of medical care in diabetes – 2013. Diabetes Care. 2013;36(Suppl 1):S11–66.10.2337/dc13-S011Search in Google Scholar
3. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977–86.10.1056/NEJM199309303291401Search in Google Scholar
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352: 837–53.10.1016/S0140-6736(98)07019-6Search in Google Scholar
5. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Diabetes Care 2007;30:2399–400.10.2337/dc07-1752Search in Google Scholar PubMed
6. Rinaldi S, Rohrmann S, Jenab M, Biessy C, Sieri S, Palli D, et al. Glycosylated hemoglobin and risk of colorectal cancer in men and women, the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2008;17:3108–15.10.1158/1055-9965.EPI-08-0495Search in Google Scholar PubMed
7. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010;362:800–11.10.1056/NEJMoa0908359Search in Google Scholar PubMed PubMed Central
8. Hanas R, John G, International Hb ACC. 2010 consensus statement on the worldwide standardization of the hemoglobin A1c measurement. Clin Chem 2010;56:1362–4.10.1373/clinchem.2010.150540Search in Google Scholar PubMed
9. Hoelzel W, Weykamp C, Jeppsson JO, Miedema K, Barr JR, Goodall I, et al. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 2004;50:166–74.10.1373/clinchem.2003.024802Search in Google Scholar PubMed
10. Little RR, Vesper H, Rohlfing CL, Ospina M, Safar-Pour S, Roberts WL. Validation by a mass spectrometric reference method of use of boronate affinity chromatography to measure glycohemoglobin in the presence of hemoglobin S and C traits. Clin Chem 2005;51:264–5.10.1373/clinchem.2004.043141Search in Google Scholar PubMed
11. Weykamp C, Waenink-Wieggers H, Kemna E, Siebelder C. HbA1c: performance of the Sebia Capillarys 2 Flex Piercing. Clin Chem Lab Med 2013;51:e129–31.10.1515/cclm-2012-0560Search in Google Scholar PubMed
12. Lin CN, Emery TJ, Little RR, Hanson SE, Rohlfing CL, Jaisson S, et al. Effects of hemoglobin C, D, E, and S traits on measurements of HbA1c by six methods. Clin Chim Acta 2012;413:819–21.10.1016/j.cca.2011.12.019Search in Google Scholar
13. Weykamp CW, Penders TJ. Mechanism and speed of reactions between haemoglobin and glucose consequences for the measurement of glycosylated haemoglobins in patient material. Clin Chim Acta 1982;125:341–50.10.1016/0009-8981(82)90265-0Search in Google Scholar
14. Weykamp CW, Penders TJ, Siebelder CW, Muskiet FA, van der Slik W. Interference of carbamylated and acetylated hemoglobins in assays of glycohemoglobin by HPLC, electrophoresis, affinity chromatography, and enzyme immunoassay. Clin Chem 1993;39:138–42.10.1093/clinchem/39.1.138Search in Google Scholar
15. Weykamp CW, Mosca A, Gillery P, Panteghini M. The analytical goals for hemoglobin A(1c) measurement in IFCC units and National Glycohemoglobin Standardization Program Units are different. Clin Chem 2011;57:1204–6.10.1373/clinchem.2011.162719Search in Google Scholar PubMed
16. Goodall I, Colman PG, Schneider HG, McLean M, Barker G. Desirable performance standards for HbA(1c) analysis – precision, accuracy and standardisation: consensus statement of the Australasian Association of Clinical Biochemists (AACB), the Australian Diabetes Society (ADS), the Royal College of Pathologists of Australasia (RCPA), Endocrine Society of Australia (ESA), and the Australian Diabetes Educators Association (ADEA). Clin Chem Lab Med 2007;45:1083–97.10.1515/CCLM.2007.158Search in Google Scholar PubMed
17. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2011;57:e1–47.10.1373/clinchem.2010.161596Search in Google Scholar PubMed
18. Roberts WL, Safar-Pour S, De BK, Rohlfing CL, Weykamp CW, Little RR. Effects of hemoglobin C and S traits on glycohemoglobin measurements by eleven methods. Clin Chem 2005;51:776–8.10.1373/clinchem.2004.047142Search in Google Scholar PubMed
19. Weykamp CW, Miedema K, de Haan T, Doelman CJ. Carbamylated hemoglobin interference in glycohemoglobin assays. Clin Chem 1999;45:438–40.10.1093/clinchem/45.3.438Search in Google Scholar
20. Little RR, Roberts WL. A review of variant hemoglobins interfering with hemoglobin A1c measurement. J Diabetes Sci Technol 2009;3:446–51.10.1177/193229680900300307Search in Google Scholar PubMed PubMed Central
©2015 by De Gruyter
